Significance of micrometastases in prostate cancer

被引:31
作者
Fujisawa, Masato [1 ]
Miyake, Hideaki [1 ]
机构
[1] Kobe Univ, Grad Sch Med, Div Urol, Chuo Ku, Kobe, Hyogo 6500017, Japan
来源
SURGICAL ONCOLOGY-OXFORD | 2008年 / 17卷 / 03期
关键词
Prostate cancer; PSA; Micrometastasis; PCR; Immunohistochemistry;
D O I
10.1016/j.suronc.2008.05.002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Pelvic lymph node metastases have been considered the most potent factor associated with disease recurrence in patients undergoing radical prostatectomy for localized prostate cancer. Routine pathological examination, however, can miss micrometastatic tumor foci in the lymph nodes of patients with prostate cancer, resulting in confused tumor staging and clinical decision-making. Accordingly, intensive efforts have been made to develop a procedure for efficaciousty detecting micrometastases in pelvic lymph nodes using several kinds of molecular and histopathological techniques targeting genes specifically expressed in the prostate, such as prostate-specific antigen and prostate-specific membrane antigen. Although some of these techniques have been shown to achieve significantly higher sensitivity for detecting micrometastatic prostate cancer cells in surgically removed pelvic nodes during radical prostatectomy than conventional pathological examination, there have not been any methods introduced into clinical practice. In this review, we attempted to summarize recent advances in the field of "micrometastases" in prostate cancer in order to clarify the clinical significance of micrometastases in patients undergoing radical prostatectomy and to suggest limitations to be overcome before developing a reliable model for clinical application. (C) 2008 Elsevier Ltd. All rights reserved.
引用
收藏
页码:247 / 252
页数:6
相关论文
共 56 条
  • [1] Bangma CH, 2000, MICROSC RES TECHNIQ, V51, P430, DOI 10.1002/1097-0029(20001201)51:5<430::AID-JEMT5>3.0.CO
  • [2] 2-1
  • [3] Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era
    Boorjian, Stephen A.
    Thompson, R. Houston
    Siddiqui, Sameer
    Bagniewski, Stephanie
    Bergstralh, Erik J.
    Karnes, R. Jeffrey
    Frank, Igor
    Blute, Michael L.
    [J]. JOURNAL OF UROLOGY, 2007, 178 (03) : 864 - 870
  • [4] Bussemakers MJG, 1999, CANCER RES, V59, P5975
  • [5] Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: Intermediate-term results
    Catalona, WJ
    Smith, DS
    [J]. JOURNAL OF UROLOGY, 1998, 160 (06) : 2428 - 2434
  • [6] de Kok JB, 2002, CANCER RES, V62, P2695
  • [7] DEGUCHI T, 1993, CANCER RES, V53, P5350
  • [8] Prospective analysis of prostate-specific markers in pelvic lymph nodes of patients with high-risk prostate cancer
    Ferrari, AC
    Stone, NN
    Eyler, JN
    Gao, M
    Mandeli, J
    Unger, P
    Gallagher, RE
    Stock, R
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (20) : 1498 - 1504
  • [9] INCIDENCE OF OCCULT LYMPH-NODE METASTASES IN PATHOLOGICAL STAGE-C (PT3NO) PROSTATE-CANCER
    FREEMAN, JA
    ESRIG, D
    GROSSFELD, GD
    STEIN, JP
    CHEN, SC
    YOUNG, LL
    TAYLOR, CR
    SKINNER, DG
    LIESKOVSKY, G
    COTE, RJ
    [J]. JOURNAL OF UROLOGY, 1995, 154 (02) : 474 - 478
  • [10] Detection of prostatic specific membrane antigen messenger RNA using immunobead reverse transcriptase polymerase chain reaction
    Ghossein, RA
    Osman, I
    Bhattacharya, S
    Ferrara, J
    Fazzari, M
    Cordon-Cardo, C
    Scher, HI
    [J]. DIAGNOSTIC MOLECULAR PATHOLOGY, 1999, 8 (02) : 59 - 65